Neonatal outcome in patients with rheumatic disease

Lupus

Volumn 13, Issue 9, 2004, Pages 718-723

  Motta, M ^a   Tincani, A ^c   Lojacono, A ^b   Faden, D ^b   Gorla, R ^c   Airo P ^c   Neri, F ^d   Gasparoni, A ^a   Ciardelli, L ^e   De Silvestri, A ^e   Marconi, M ^e   Chirico, G ^a  

^a Neonatal Intensive Care Unit   (Italy)

^b Obstetrics and Gynecology   (Italy)

^c Rheumatology and Clinical Immunology   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Antiphospholipid syndrome; Breastfeeding; Immune system; Neonatal lupus erythematosus; Neonatal thrombocytopenia; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BETAMETHASONE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHOTREXATE; STEROID; VINCA ALKALOID;

ANTIPHOSPHOLIPID SYNDROME; BRAIN HEMORRHAGE; BREAST FEEDING; CONFERENCE PAPER; CONGENITAL HEART BLOCK; FETUS DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; LUPUS ERYTHEMATOSUS; MATERNAL DISEASE; NEWBORN DISEASE; OSTEOLYSIS; PLACENTAL TRANSFER; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PREVALENCE; PRIORITY JOURNAL; RHEUMATIC DISEASE; SEX RATIO; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; FEMALE; HEART BLOCK; HUMANS; INFANT, NEWBORN; LUPUS; PREGNANCY; PREGNANCY COMPLICATIONS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTORS;

EID: 4644239693     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203403lu2002oa     Document Type: Conference Paper

References (43)

1. Buyon JP, Nugent D, Mellins E, Sandborg C. Maternal immunologic disease and neonatal disorders. NeoReviews 2002; 3: e3.
2. Buyon JP, Hiebert R, Copel J et al. Autoimmune-associated congenital heart block: mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-1666.
3. Brucato A, Frassi M, Franceschini F et al. Congenital heart block risk to newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis. A prospective study of 100 women. Arthritis Rheum 2001; 44: 1832-1835.
4. Taylor-Albert E, Reichlin M, Toews WH et al. Delayed dilated cardiomyopathy as a manifestation of neonatal lupus: case reports, autoantibody analysis, and management. Pediatrics 1997; 99: 733-735.
5. Moak JP, Barron KS, Hougen TJ et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37: 238-242.
6. Eronen M, Siren MK, Ekblad H et al. Short- and long-term outcome of children with congenital complete heart block diagnosed in utero or as a newborn. Pediatrics 2000; 106: 86-91.
7. Udink ten Cate FE, Breur JM, Cohen MI et al. Dilated cardiomyopathy in isolated congenital complete atrioventricular block: early and long-term risk in children. J Am Coll Cardiol 2001; 37: 1129-1134.
8. Cimaz R, Airoldi ML, Careddu P et al. Transient neonatal bradycardia without heart block associated with anti-Ro antibodies [letter]. Lupus 1997; 6: 487-488.
9. Cimaz R, Meroni PL, Brucato A et al. Concomitant disappearance of electrocardiographic abnormalities and of acquired maternal autoantibodies during the first year of life in infants who had QT interval prolongation and anti-SSA/Ro positivity without congenital heart block at birth. Arthritis Rheum 2003; 48: 266-268.
10. Sonesson SE, Salomonsson S, Jacobsson LA, Bremme K, Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50: 1253-1261.
11. Neiman AR, Lee LA, Weston WL, Buyon JP. Isolated cutaneous manifestations of neonatal lupus: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 137: 674-680.
12. Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics 2002; 109: el 1.
13. Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematous: a prospective study of infant born to mothers with anti-Ro antibodies. J Pediatr 2003; 142: 678-683.
14. Martin V, Lee LA, Askanase AD, Katholi M, Buyon JP. Long-term follow-up of children with neonatal lupus and their unaffected siblings. Arthritis Rheum 2002; 46: 2377-2383.
15. Gill KK, Kelton JG. Management of idiopathic thrombocytopenic purpura in pregnancy. Semin Hematol 2000; 37: 275-289.
16. Bussel JB. Immune thrombocytopenia in pregnancy: autoimmune and alloimmune. J Reprod Immunol 1997; 37: 35-61.
17. Christiaens GCML, Nieuwenhuis HK, Bussel JB. Comparison of platelet counts in first and second newborns of mothers with immune thrombocytopenic purpura. Obstet Gynecol 1997; 90: 546-552.
18. McCrae KR, Samuels P, Schreiber AD. Pregnancy-associated thrombocytopenia: pathogenesis and management. Blood 1992; 80: 2697-2714.
19. Letsky EA, Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Br J Haematol 1996; 95: 21-26.
20. Burrows RF, Kelton JG. Pregnancy in patients with idiopathic thrombocytopenic purpura: assessing the risks for the infant at delivery. Obstet Gynecol Surv 1993; 48: 781-788.
21. Tchemia G, Morel-Kopp MC, Yvart J, Kaplan C. Neonatal thrombocytopenia and hidden maternal autoimmunity. Br J Haematol 1993; 84: 457-463.
22. Payne SD, Resnik R, Moore TR, Hedriana HL, Kelly TF. Maternal characteristics and risk of severe neonatal thrombocytopenia and intracranial hemorrhage in pregnancies complicated by autoimmune thrombocytopenia. Am J Obstet Gynecol 1997; 177: 149-155.
23. 3. Anesth Analg 1997; 85: 385-388.
24. Kelton JG. Idiopathic thrombocytopenic purpura complicating pregnancy. Blood Rev 2002; 16: 43-46.
25. Burrows RF, Kelton JG. Low fetal risks in pregnancies associated with idiopathic thrombocytopenic purpura. Am J Obstet Gynecol 1990; 163: 1147-1150.
26. Roberts I, Murray NA. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 2003; 88: F359-F364.
27. British Committee for Standards in Haematology. Transfusion guidelines for neonates and older children. Brit J Haematol 2004; 124: 433-453.
28. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
29. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
30. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunological manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-1027.
31. Tincani A, Lojacono A, Taglietti M et al. Pregnancy and neonatal outcome in primary antiphospholipid syndrome. Lupus 2002; 11: 649.
32. Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus 2002; 11: 4-10.
33. Neri F, Chimini L, Bonomi F et al. Neuropsycological development of children born to patients with systemic lupus erythematous. Lupus 2004 (in press).
34. Motta M, Tincani A, Frassi M et al. Anticardiolipin and anti-β2 glycoprotein I antibodies detection in infants born from mother with Antiphospholipid Syndrome. (Abstract) European Forum on Antiphospholipid Antibodies, Royal Free Hospital, London, 16-17 January 2004.
35. Avcin T, Ambrozic A, Kuhar M, Kveder T, Rozman B. Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology 2001; 40: 565-573.
36. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 6th edn. Baltimore: Lippincott Williams and Wilkins, 2001.
37. Prevot A, Martini S, Guignard JP. In utero exposure to immunosuppressive drugs. Biol Neonate 2002; 81: 73-81.
38. Motta M, Tincani A, Faden D, Zinzini E, Chirico G. Antimalarial agents in pregnancy. Lancet 2002; 359: 524-525.
39. Klinger G, Morad Y, Westall CA et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001; 358: 813-814.
40. Costedoat-Chalumeau N, Amoura Z, Duhaut P et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. A study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48: 3207-3211.
41. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108: 776-789.
42. Cimaz R, Meregalli E, Biggioggero M et al. Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Tox Lett 2004; 149: 155-162.
43. Airo P, Danieli E, Antonioli CM et al. Response to C. tetani toxoid vaccination in children from mothers with autoimmune rheumatic disorders. (Abstract) Ann Rheum Dis 2004; 63(suppl): 532.